Novigenix acquires blood-based molecular diagnostics test Colox® and prepares its further commercial rollout in Switzerland and Europe to improve the early detection of colorectal cancer
LAUSANNE, Switzerland, February 12, 2015 – Molecular diagnostics company Novigenix SA announced today it acquired Colox®, a new molecular blood test for the detection of colorectal cancer and pre-cancerous lesions (adenomatous polyps). Colox has been approved for sale in Europe, and has been launched commercially in Switzerland. Novigenix aims to increase the availability of Colox